SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
June 4, 2001
------------------------------
(Date of Earliest Event Reported)
PHAGE THERAPEUTICS INTERNATIONAL INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
FLORIDA
------------------------
(State of Incorporation)
91-1930691
--------------------- -------------------
(Commission File No.) (I.R.S. Employer Identification No.)
19017 120th Avenue NE, Suite 102, Bothell, Washington 98011
-------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(425) 481-6255
------------------------------
(Registrant's telephone number, including area code)
ITEM 5. OTHER EVENTS
On June 4, 2001 the Registrant issued the press release attached hereto as
Exhibit 1 which is incorporated herein by reference. The press release relates
to an announcement by the Registrant of the adjournment of the Annual General
Meeting to Monday, September 10, 2001 at 11 a.m. (the "AGM").
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
1. Press Release dated June 4, 2001.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: June 4, 2001
PHAGE THERAPEUTICS INTERNATIONAL
INC.
(Registrant)
By: /s/ Darren Pylot
-------------------------------------
Darren Pylot, Chief Financial Officer & Director
Exhibit 1
---------
June 4, 2001
OTCBB SYMBOL: PTXX
NEWS RELEASE
ANNUAL GENERAL MEETING ON SEPTEMBER 10, 2001
BOTHELL, WASHINGTON - Phage Therapeutics International Inc. (OTCBB:PTXX) (the
"Company") wishes to announce that it has adjourned its annual general meeting
to September 10, 2001 at 11 a.m. (the "AGM"). The AGM will be held at the
Company's headquarters at 19017 120th Avenue NE, Suite 102, Bothell, Washington.
The shareholders of record will be re- set and announced closer to the AGM date.
Phage Therapeutics International Inc. is a Florida corporation, doing business
in Washington State, formed to develop, manufacture and achieve regulatory
approval of bacteriophage pharmaceutical products for the treatment of
antibiotic-resistant and other bacterial infections.
Currently, the Company has 13,188,301 shares issued and outstanding.
For Investor Relations information, please contact:
Chris Tomanik 1-888-224-4144
PHAGE THERAPEUTICS INTERNATIONAL INC.
"Darren Pylot"
Darren Pylot,
Chief Financial Officer & Director
THE SEC AND NASD HAVE NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking statements and comments in this press release are made pursuant
to safe harbor provisions of the Securities Exchange Act of 1934. Certain
statements which describe the Company's intentions, expectations or predictions,
are forward-looking and are subject to important risks and uncertainties. The
results or events predicted in these statements may differ materially from
actual results or events. Factors which could cause results or events to differ
from current expectations include, among other things: the impact of rapid
technological and market change; general industry and market conditions and
growth rates; international growth and global economic conditions, particularly
in emerging markets and including interest rates and currency exchange rate
fluctuations; and the impact of consolidations in the technology industry. These
risks may further be discussed in periodic reports and registration statements
to be filed by the Company from time to time with the Securities and Exchange
Commission in the future.